endocrine · Mechanism Report

Does ovarian aging during the menopausal transition lower testosterone levels?

Ovarian aging reduces androgen biosynthetic capacity over time, but during the menopausal transition circulating total testosterone often remains stable and free (bioactive) testosterone can be maintained or transiently increase due to compensatory LH stimulation and falling SHBG.

PlausibleJune 19, 202610 Sources

This is what AI claimed

Ovarian aging in the menopausal transition is associated with a decline in ovarian androgen production, contributing to lower testosterone levels.

2 of 4 paths supported

Executive summary

The claim links follicular depletion and reduced ovarian androgen output to lower systemic testosterone, but the mechanism graph and evidence emphasize compensatory processes during the transition. Rising LH can stimulate ovarian stroma to sustain androgen production and declining SHBG increases bioavailable testosterone, so a long-term decline in ovarian capacity may not produce an immediate fall in circulating bioactive testosterone.

Verified conclusion

The transition through menopause marks a significant shift in female endocrinology, but the relationship between ovarian aging and testosterone levels is more nuanced than the linear decline observed with estrogens.

Clinical evidence and hormonal trends

Current research indicates that while ovarian aging eventually reduces androgen output, the menopausal transition does not always result in an immediate drop in circulating testosterone.

Longitudinal patterns: Data from the Study of Women's Health Across the Nation (SWAN), which followed women through the menopausal transition, suggests that total testosterone levels remain relatively stable or may even increase slightly during the late perimenopausal phase before gradually declining with age.
Total vs. Bioavailable levels: While total testosterone may stay stable, the transition is often characterized by a decrease in sex hormone-binding globulin (SHBG). This drop in SHBG can lead to an increase in the "free androgen index," meaning the amount of biologically active testosterone may actually rise relatively during perimenopause, even as ovarian function shifts.
Ovarian contribution: The ovaries remain a significant source of androgens throughout a woman’s life. In premenopausal women, the ovaries contribute approximately 25% of circulating testosterone directly and another 25% via the peripheral conversion of androstenedione. Even after the cessation of follicular activity, the ovarian stroma and theca cells can continue to produce androgens.

Mechanistic explanations

The maintenance of androgen levels during the menopausal transition is driven by complex feedback loops and tissue-specific enzyme activity.

LH stimulation: As ovarian follicles are depleted, the lack of negative feedback from estrogen and inhibin causes a rise in luteinizing hormone (LH). This elevated LH can hyper-stimulate the remaining ovarian theca cells and stroma, maintaining or even boosting the production of testosterone and androstenedione.
Steroidogenic enzyme shifts: Ovarian aging eventually leads to a decrease in key steroidogenic enzymes, such as 17β-HSD and CYP19 (aromatase). However, this depletion typically occurs over a long timeframe, often manifesting significantly only a decade or more after the final menstrual period.
Adrenal synergy: The adrenal glands provide the other major portion of a woman's androgen pool. During the midlife transition, adrenal production of DHEA and DHEAS remains a relatively stable substrate for peripheral conversion into testosterone, which helps buffer the decline in ovarian follicular output.

Bottom line

While ovarian aging eventually leads to a long-term reduction in androgen biosynthetic capacity, the menopausal transition itself is not always associated with lower testosterone. Due to compensatory LH stimulation of the ovarian stroma and fluctuations in SHBG, many women maintain stable or even elevated free testosterone levels during perimenopause.